Trial
NCT03167151
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Oxford
Collaborators
Merck Sharp & Dohme LLC
Condition
Non-muscle Invasive Bladder Cancer (NMIBC)
Intervention
Pembrolizumab
Why stopped
The study failed to recruit within the permitted timeframe
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-31